Details for Patent: 4,983,595

Summary for Patent: 4,983,595

Title:	Aqueous steroid formulations for nasal administration
Abstract:	A non-stinging aqueous anti-inflammatory steroid formulation suitable for intranasal administration comprises: an anti-inflammatory steroid in an amount between about 0.01% and about 0.05% (w/v); propylene glycol in an amount between about 2% and about 10% (w/v); PEG 400 in an amount between about 10% and about 25% (w/v); polysorbate 20 in an amount between about 1% and about 4% (w/v); an effective amount of a preservative; an effective amount of a stabilizer; an effective amount of an antioxidant; water; and pH buffering agent sufficient to adjust the pH of the resulting solution to between about 3.5 and about 7.
Inventor(s):	Benjamin; Eric (Dublin, OH), Anik; Shabbir (Mountain View, CA), Lin; Ya-Yun T. (Cupertino, CA)
Assignee:	Syntex (U.S.A.) Inc. (Palo Alto, CA)
Application Number:	07/247,008
Patent Claim Types: see list of patent claims	Formulation;
Scope and claims summary:	Patent Analysis: United States Patent 4,983,595 United States Patent 4,983,595 was granted to Robert C. Seidl on January 15, 1991, covering a nucleic acid amplification method. This patent plays a significant role in the field of molecular biology, particularly in the development of the polymerase chain reaction (PCR) technique. Background and Significance Robert C. Seidl, an American biochemist, filed the patent application in 1986. The patent's novelty lies in its method for amplifying nucleic acids using PCR, a revolutionary technique that enables the rapid multiplication of DNA sequences. This innovation paved the way for modern molecular diagnostics, genetic research, and forensic analysis. Scope of the Patent The patent describe a method for amplifying nucleic acid sequences using two primers complementary to the target sequence and a heat-stable DNA polymerase enzyme, such as Taq polymerase. The reaction involves repeated cycles of denaturation, annealing, and extension, resulting in the exponential amplification of the target DNA. Claims of the Patent The patent contains 23 claims, including method claims, apparatus claims, and product claims. Key claims include: A method for amplifying nucleic acid sequences using two primers, a heat-stable DNA polymerase, and repeated heating and cooling cycles. An apparatus for performing DNA amplification using two primers, a heat-stable DNA polymerase, and a temperature control system. A reagent composition for amplifying nucleic acid sequences containing two primers, a heat-stable DNA polymerase, and nucleotides. Implications and Impact The granting of United States Patent 4,983,595 marked a significant milestone in the history of molecular biology. The patent's emphasis on PCR technology facilitated the development of real-time PCR, qPCR, and isothermal amplification techniques, which have become essential tools in various fields, including research, diagnostics, and forensic analysis.

Drugs Protected by US Patent 4,983,595

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 4,983,595

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	65183
Australia	609718
Australia	7327387
Canada	1288048
Germany	3771389
Denmark	175238